Anavex Life Sciences Corp...

NASDAQ: AVXL · Real-Time Price · USD
9.91
-0.20 (-1.98%)
At close: Aug 15, 2025, 3:59 PM
10.26
3.48%
After-hours: Aug 15, 2025, 06:30 PM EDT

Anavex Life Sciences Income Statement

Financials in USD. Fiscal year is October - September.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Sep 30, 2024 Sep 30, 2023 Sep 30, 2022 Sep 30, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a
Operating Income
-52.88M -55.76M -50.99M -41.92M
Interest Income
7.32M 6.52M 946.99K 26.26K
Pretax Income
-43M -47.5M -47.62M -37.64M
Net Income
-43M -47.51M -47.98M -37.91M
Selling & General & Admin
11.04M 12.04M 13.07M 9.15M
Research & Development
41.84M 43.72M 37.92M 32.98M
Other Expenses
n/a n/a n/a -186K
Operating Expenses
52.88M 55.76M 50.99M 41.95M
Interest Expense
n/a 964K 946.99K n/a
Selling & Marketing Expenses
n/a n/a n/a 131K
Cost & Expenses
52.88M 55.76M 50.99M 41.95M
Income Tax Expense
-2.29M 7K 358.49K 267.56K
Shares Outstanding (Basic)
83.47M 79.79M 76.91M 69.8M
Shares Outstanding (Diluted)
83.47M 79.79M 76.91M 69.8M
EPS (Basic)
-0.52 -0.6 -0.62 -0.54
EPS (Diluted)
-0.52 -0.6 -0.62 -0.54
EBITDA
-45.29M -55.76M -50.94M -37.38M
EBIT
-45.29M -53.04M -50.94M -42.19M
Depreciation & Amortization
50.59M -2.72M -3.32M 37.45M